These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26301800)

  • 1. Somatic Mutation Spectrum of Non-Small-Cell Lung Cancer in African Americans: A Pooled Analysis.
    Araujo LH; Lammers PE; Matthews-Smith V; Eisenberg R; Gonzalez A; Schwartz AG; Timmers C; Shilo K; Zhao W; Natarajan TG; Zhang J; Yilmaz AS; Liu T; Coombes K; Carbone DP
    J Thorac Oncol; 2015 Oct; 10(10):1430-6. PubMed ID: 26301800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
    Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
    Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
    Leidner RS; Fu P; Clifford B; Hamdan A; Jin C; Eisenberg R; Boggon TJ; Skokan M; Franklin WA; Cappuzzo F; Hirsch FR; Varella-Garcia M; Halmos B
    J Clin Oncol; 2009 Nov; 27(33):5620-6. PubMed ID: 19786660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
    Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
    Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
    Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
    Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.
    Cote ML; Haddad R; Edwards DJ; Atikukke G; Gadgeel S; Soubani AO; Lonardo F; Bepler G; Schwartz AG; Ethier SP
    J Thorac Oncol; 2011 Mar; 6(3):627-30. PubMed ID: 21317742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
    Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.
    Araujo LH; Timmers C; Bell EH; Shilo K; Lammers PE; Zhao W; Natarajan TG; Miller CJ; Zhang J; Yilmaz AS; Liu T; Coombes K; Amann J; Carbone DP
    J Clin Oncol; 2015 Jun; 33(17):1966-73. PubMed ID: 25918285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
    Reinersman JM; Johnson ML; Riely GJ; Chitale DA; Nicastri AD; Soff GA; Schwartz AG; Sima CS; Ayalew G; Lau C; Zakowski MF; Rusch VW; Ladanyi M; Kris MG
    J Thorac Oncol; 2011 Jan; 6(1):28-31. PubMed ID: 21107288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
    Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
    PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.
    Lusk CM; Watza D; Dyson G; Craig D; Ratliff V; Wenzlaff AS; Lonardo F; Bollig-Fischer A; Bepler G; Purrington K; Gadgeel S; Schwartz AG
    Clin Cancer Res; 2019 Jul; 25(14):4300-4308. PubMed ID: 30979741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial diversity of actionable mutations in non-small cell lung cancer.
    Bollig-Fischer A; Chen W; Gadgeel SM; Wenzlaff AS; Cote ML; Schwartz AG; Bepler G
    J Thorac Oncol; 2015 Feb; 10(2):250-5. PubMed ID: 25376516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
    Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
    Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
    Cardarella S; Ortiz TM; Joshi VA; Butaney M; Jackman DM; Kwiatkowski DJ; Yeap BY; Jänne PA; Lindeman NI; Johnson BE
    J Thorac Oncol; 2012 Dec; 7(12):1767-1774. PubMed ID: 23154547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.
    Li C; Hao L; Li Y; Wang S; Chen H; Zhang L; Ke B; Yin Y; Suo H; Sun B; Zhang B; Wang C
    PLoS One; 2014; 9(9):e107276. PubMed ID: 25198510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
    Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
    J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
    Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
    Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.